Croda International

What they make

1 input Croda International supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Intelligence

What's known

Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.

• Did you know2024

  Croda is best known as a maker of cosmetic ingredients — the emulsifiers that keep a lotion from separating, the surfactants and emollients in sunscreen, shampoo and skin care. But the same firm became a linchpin of the mRNA-vaccine revolution. Through its acquisition of Avanti Polar Lipids, Croda supplies the high-purity lipids used to build the lipid nanoparticles (LNPs) — the microscopic fatty bubbles that encapsulate fragile mRNA and ferry it into human cells — including for the Pfizer-BioNTech COVID-19 vaccine. So the company behind the feel of your face cream also makes the molecular delivery vehicle that carried mRNA into billions of arms. It's not a coincidence of unrelated businesses but a deep technical kinship: emulsifying oils into a stable cream and assembling lipids into a nanoparticle that protects genetic cargo are both fundamentally the chemistry of surfactants and lipids. The cosmetics counter and the mRNA vaccine, improbably, draw on the same molecular science — and on the same British company.

  Croda International Plc (CRDA) ↗

• Chokepoint2024

  The lipids that make mRNA vaccines possible are a deep, scarce chokepoint, and Croda sits squarely in it. An mRNA-LNP vaccine needs specialized lipids — an ionizable lipid plus helper lipids, made to pharmaceutical purity at scale — and only a tiny set of suppliers can produce them: Croda (via Avanti), Japan's NOF, Merck/MilliporeSigma and CordenPharma among them. During the COVID vaccine ramp, the availability of these lipids was a genuine binding constraint on how fast doses could be made, sometimes more limiting than the mRNA itself. So a cosmetic-ingredients company is one of the handful of firms gating the supply of a foundational input to mRNA medicine — and because mRNA is now being pursued for cancer vaccines, gene therapies and more, that lipid chokepoint will matter well beyond COVID. It's the same lesson seen with mRNA's other reagents (Maravai's CleanCap, Hongene's nucleotides): the future of a glamorous new medicine rests on a few specialist suppliers of unglamorous building blocks, several of them companies the public knows for entirely different products. [verify: Croda/Avanti LNP-lipid chokepoint real; lipids binding constraint in COVID ramp well-documented]

  Croda International Plc (CRDA) ↗

• Origin2024

  Croda's leap from sheep to mRNA is one of the more poetic origin arcs in this radar. The company was founded in 1925 in Yorkshire to extract and refine lanolin — the waxy grease combed from raw sheep's wool — into a usable ingredient for cosmetics, lubricants and industrial uses. From that humble base in animal-derived oils and fats, Croda built nearly a century of expertise in lipids and surfactants, gradually climbing into high-value specialty actives, and in 2020 reached the frontier of medicine by acquiring the lipid specialist Avanti to supply mRNA-vaccine delivery lipids. It also reshaped itself by selling its commodity industrial-chemicals arm in 2022 to concentrate on consumer care and life sciences. So a firm that started by purifying wool grease for face cream now makes the lipids that deliver genetic medicine — an unbroken thread of lipid chemistry running from a 1920s sheep-shearing byproduct to the cutting edge of vaccinology, a reminder that today's high-tech suppliers often grew from astonishingly humble natural-material roots.

  Croda International Plc (CRDA) ↗